Adel Naimi

905 citations
15 papers · 643 · 1 hit paper · h-index 10

Impact in

  • Oncology top 10%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
    • Immune Cell Function and Interaction
    • Immunotherapy and Immune Responses
    • Immune cells in cancer

Papers in

    • Cell death mechanisms and regulation 5
    • RNA Interference and Gene Delivery 3
    • Retinoids in leukemia and cellular processes 2
    • Mesenchymal stem cell research 4

Adel Naimi

15 papers receiving 638 citations

Adel Naimi's Hit Papers

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons 2022 · 306 citations
3060+1+2Years since publication100200300

Peers

Adel Naimi
Comparison fields: 5 of 77
  • Oncology 291
  • Immunology 199
  • Genetics 73
  • Cancer Research 66
  • Molecular Biology 226
Replace Meng Lu with:
Meng Lu China
Dongsheng Xu China
Masakazu Yasumaru Japan
Ji‐Hyeon Ju South Korea
Hongde Li China
Amanda Moyer United States
Saleh Yazdani Netherlands
Beibei Ni China
Shunzong Yuan China
Jiaxuan Chen China
Adel Naimi relative to Meng Lu China Meng Lu's profile →
Citations per field
00.5×3.0×
Meng Lu · 1×
Citations per year

Countries citing papers authored by Adel Naimi

Since Specialization
Citations

This map shows the geographic impact of Adel Naimi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adel Naimi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adel Naimi more than expected).

Fields of papers citing papers by Adel Naimi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adel Naimi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adel Naimi. The network helps show where Adel Naimi may publish in the future.

Co-authors

The 25 scholars most cited alongside Adel Naimi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Adel Naimi Line = papers co-authored together Adel Naimi links everyone, so they are left out of the graph.

All Works

15 of 15 papers shown
#Work
1
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Hit paper breakdown →
2022306
2 202065
3 202156
4 201837
5 201736
6 201836
7 202132
8 201919
9 202219
10 20219
11 20209
12 20218
13 20206
14 20203
15 20212

About Adel Naimi

Adel Naimi is a scholar working on Molecular Biology, Genetics, Oncology, Immunology and Hematology, having authored 15 papers that have together received 643 indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (5 papers), Mesenchymal stem cell research (4 papers), RNA Interference and Gene Delivery (3 papers), Hematopoietic Stem Cell Transplantation (3 papers), Phagocytosis and Immune Regulation (2 papers), CAR-T cell therapy research (2 papers), NF-κB Signaling Pathways (2 papers) and Retinoids in leukemia and cellular processes (2 papers). The work is most often cited by research in Oncology (291 citations), Immunology (199 citations), Genetics (73 citations), Cancer Research (66 citations) and Molecular Biology (226 citations). Adel Naimi has collaborated with scholars based in Iran, Iraq and Thailand. Frequent co-authors include Ali Hassanzadeh, Wanich Suksatan, Alexei Valerievich Yumashev, Lakshmi Thangavelu, Ehsan Razeghian, Ahmed Raji, Ali Noroozi‐Aghideh, Supat Chupradit, Navid Shomali and Ali Adili. Their work appears in journals such as Journal of Cellular Physiology, Anti-Cancer Agents in Medicinal Chemistry, Journal of Clinical Laboratory Analysis, Biomedicine & Pharmacotherapy and Advanced Pharmaceutical Bulletin.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact